Introduction: Graft dysfunction after liver transplantation is marked by elevated liver enzymes. Taurine, an antioxidant amino acid, may support graft function. This study evaluated taurine's effect on post-transplant liver biomarkers.
Methods: In this randomized, double-blind trial, adults undergoing liver transplantation (Sept 2020-June 2021) were enrolled. Exclusions were death within 72 h or multi-organ transplant. Patients received oral taurine or placebo (2 g/day) from transplant day to day 30. The primary outcomes were changes in liver enzymes and bilirubin. Secondary outcomes included mortality, intensive transplantation unit (ITU)/hospital stay, and ventilation duration.
Results: Of 225 patients, 56 were excluded (29 refusals, 27 early deaths). The 169 analyzed patients were evenly randomized. The taurine group had significantly greater reductions in aspartate aminotransferase (AST), total bilirubin, and international normalized ratio (INR). Taurine was also associated with significantly lower mortality (p < 0.05), shorter ITU stay (mean difference: -4.09 days), shorter hospital stay (mean difference: -3.49 days), and reduced mechanical ventilation duration (mean difference: -20.06 h) compared to placebo. All patients showed expected post-operative declines in alanine aminotransferase (ALT), AST, and bilirubin.
Conclusion: Supplementation with 2 g/day taurine for 30 days after transplantation was associated with improved graft function markers (AST, total bilirubin, INR) and better clinical recovery outcomes. These results suggest taurine may be a beneficial adjunct therapy to support early post-transplant recovery.
扫码关注我们
求助内容:
应助结果提醒方式:
